A PODular Therapies-as-a-Service Approach To Fundamentally Change the CAR-T Cell Therapy Landscape
June 14, 2022
Tags:
aCGT Vector is developing disruptive technology that is poised to transform the way CAR-T and other autologous cell therapies are manufactured, locating PODular “GMP-in-a-POD” distributed manufacturing systems in cancer centers of excellence.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
